From: Is sirolimus a therapeutic option for patients with progressive pulmonary lymphangioleiomyomatosis?
Pat. ID | FEV1(l/% pred.) | FVC (l/% pred.) | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Baseline | 3 months | p | 6 months | p | baseline | 3 months | p | 6 months | p | |||||||
1 | 1.79 | 62.0 | 1.39 | 49.0 | 2.22 | 77.6 | 2.65 | 77.4 | 2.75 | 81.4 | 3.17 | 93.2 | ||||
2 | 1.51 | 44.8 | 1.89 | 56.1 | 1.88 | 55.3 | 3.02 | 78.3 | 3.27 | 84.8 | 3.26 | 84.1 | ||||
3 | 1.69 | 44.3 | 1.86 | 48.7 | 1.98 | 51.9 | 2.90 | 66.1 | 2.99 | 67.3 | 3.12 | 71.4 | ||||
4 | 1.39 | 43.7 | 1.84 | 58.4 | 2.03 | 64.4 | 2.58 | 71.7 | 3.06 | 85.5 | 3.63 | 99.3 | ||||
5 | 0.34 | 12.3 | 0.53 | 19.1 | 0.64 | 23.3 | 0.78 | 24.9 | 1.58 | 49.6 | 1.54 | 48.1 | ||||
6 | 1.00 | 29.8 | 1.35 | 41.1 | 1.41 | 42.9 | 2.86 | 74.1 | 2.91 | 76.3 | 3.56 | 93.3 | ||||
7 | 0.93 | 34.4 | 1.22 | 45.1 | 1.11 | 41.3 | 3.17 | 99.0 | 2.99 | 94.2 | 2.99 | 94.2 | ||||
8 | 0.85 | 25.8 | 1.03 | 31.3 | 1.05 | 31.9 | 2.38 | 63.4 | 3.35 | 89.1 | 2.54 | 67.2 | ||||
9 | 0.95 | 27.6 | 1.22 | 41.6 | 1.30 | 44.4 | 2.98 | 88.5 | 2.94 | 86.4 | 3.18 | 94.2 | ||||
10 | 0.49 | 22.4 | 1.03 | 47.0 | 1.08 | 48.9 | 1.40 | 52.3 | 2.48 | 90.6 | 2.61 | 95.5 | ||||
Mean ± SEM | 1.12 ± 0.15 | 36.1 ± 4.5 | 1.34 ± 0.14 | 44.0 ± 3.7 | 0.024 | 1.47 ± 0.17 | 48.1 ± 4.9 | 0.001 | 2.47 ± 0.25 | 69.2 ± 6.5 | 2.83 ± 0.16 | 80.2 ± 4.2 | 0.031 | 2.96 ± 0.19 | 83.9 ± 5.25 | 0.006 |